- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.01. | PaxMedica, Inc.: PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions | 129 | ACCESS Newswire | BOSTON, MA / ACCESSWIRE / January 14, 2025 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce... ► Artikel lesen | |
| 03.10.24 | PaxMedica, Inc. - S-1, General form for registration of securities | 5 | SEC Filings | ||
| 20.09.24 | PaxMedica, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.09.24 | PaxMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| PAXMEDICA Aktie jetzt für 0€ handeln | |||||
| 03.09.24 | BioMedNewsBreaks - PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K | 2 | iNVEZZ.com | ||
| 03.09.24 | PaxMedica, Inc.: PaxMedica Secures Immediate Exercise of Warrants | 193 | ACCESS Newswire | TARRYTOWN, NY / ACCESSWIRE / September 3, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced... ► Artikel lesen | |
| 27.08.24 | PaxMedica, Inc.: PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection | 219 | ACCESS Newswire | Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated... ► Artikel lesen | |
| 14.08.24 | PaxMedica, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 15.05.24 | PaxMedica, Inc.: PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 | 336 | GlobeNewswire (Europe) | TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the "Company" or "PaxMedica") (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological... ► Artikel lesen | |
| 23.04.24 | PaxMedica, Inc.: PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 | 189 | GlobeNewswire (Europe) | TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN - PaxMedica Inc. (Nasdaq: PXMD) (the "Company"), a leading biopharmaceutical company dedicated to advancing treatments for neurological... ► Artikel lesen | |
| 16.04.24 | PaxMedica, Inc.: PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness | 466 | GlobeNewswire (Europe) | Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously... ► Artikel lesen | |
| 11.04.24 | PaxMedica, Inc.: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission | 395 | GlobeNewswire (Europe) | TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN - PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 57,50 | +0,54 % | Tempus AI (NASDAQ:TEM) Stock Price Up 6.3% - Should You Buy? | ||
| QIAGEN | 42,895 | -0,01 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 28.01.2025 | Das Instrument O92 CA98956B1031 ZEUS NORTH AMER.MINING C. EQUITY wird cum Kapitalmassnahme gehandelt am 28.01.2025 und ex Kapitalmassnahme am 29.01.2025 The instrument O92 CA98956B1031 ZEUS NORTH AMER.MINING... ► Artikel lesen | |
| IMMUNOVANT | 21,740 | -1,50 % | Here's Why Immunovant, Inc. (IMVT) Will Double in 2025 | ||
| RECURSION PHARMACEUTICALS | 7,240 | -5,85 % | How Is The Market Feeling About Recursion Pharmaceuticals? | ||
| IMMUNOME | 11,030 | +4,95 % | Immunome Inc. - 8-K, Current Report | ||
| MAZE THERAPEUTICS | 15,950 | 0,00 % | Maze Therapeutics Prices Upsized IPO Of 8.75 Mln Shares At $16.00/shr | WASHINGTON (dpa-AFX) - Maze Therapeutics Inc. (MAZE) announced that it has priced its upsized initial public
offering of 8.75 million shares of its common stock at a public offering price... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 37,500 | +0,73 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025 | ||
| AVIDITY BIOSCIENCES | 32,930 | +0,92 % | Avidity Biosciences, Inc.: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 | Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran... ► Artikel lesen | |
| EVOTEC | 8,650 | +0,82 % | BioTech - jetzt geht's los! 100 % Chancen für Evotec, BioNxt, Bayer, Formycon und Novo Nordisk! | Der DAX 40-Index erreichte in der letzten Woche mit 21.520 Punkten ein neues Allzeithoch. Das klingt auf den ersten Blick komisch, denn die Hälfte aller Werte krebst an mehrjährigen Tiefstständen. Zugpferde... ► Artikel lesen | |
| JANUX THERAPEUTICS | 43,480 | -2,92 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 53,76 | +3,90 % | A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts | ||
| ARS PHARMACEUTICALS | 13,020 | -8,89 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
| 89BIO | 9,600 | -0,52 % | 89bio, Inc. - 8-K, Current Report | ||
| DYNE THERAPEUTICS | 14,220 | +0,57 % | Dyne Therapeutics (NASDAQ:DYN) Sees Large Volume Increase - What's Next? | ||
| VIR BIOTECHNOLOGY | 10,400 | +0,87 % | Vir Biotechnology, Inc. - 8-K, Current Report |
PAXMEDICA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,001 (+0,19 %) liegt der Kurs bei 0,690 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PAXMEDICA INC finden Sie auf Wallstreet Online.
